Cilengitide
Cilengitide is a cyclic pentapeptide (cyclo-RGDfK) integrin inhibitor that selectively antagonises alphavbeta3 and alphavbeta5 integrins, disrupting tumour angiogenesis and invasion. It has both anti-angiogenic and direct anti-tumour effects through anoikis induction. Despite promising preclinical results, Phase III trials in glioblastoma did not demonstrate survival benefit; remains an important research probe for integrin signalling.
Description
Scientific Overview: Cilengitide is a cyclic pentapeptide (cyclo-RGDfK) integrin inhibitor that selectively antagonises alphavbeta3 and alphavbeta5 integrins, disrupting tumour angiogenesis and invasion. It has both anti-angiogenic and direct anti-tumour effects through anoikis induction. Despite promising preclinical results, Phase III trials in glioblastoma did not demonstrate survival benefit; remains an important research probe for integrin signalling.
Mechanism of Action: alphavbeta3 / alphavbeta5 Integrin Inhibitor (cyclic RGD peptide)
Purity: ≥99% | Molecular Formula: C27H34N8O7
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | alphavbeta3 / alphavbeta5 Integrin Inhibitor (cyclic RGD peptide) |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C27H34N8O7 |
| CAS Number | 188968-51-6 |
